San Diego, USA / Shanghai, China, Aug 25th, 2023 - ABM Therapeutics, invested and incubated by Viva BioInnovator (VBI), announced today that its IND application for ABM-168, a self-developed MEK1/2 inhibitor has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients with advanced solid tumors, especially patients with brain metastases or primary brain tumors, aiming to explore the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-168.
ABM-168 is a highly potent allosteric MEK1/2 inhibitor. It has shown strong anti-tumor activity when used alone, or in combination with other drugs in pre-clinical animal models. Pre-clinical research has also shown that ABM-168 had an excellent ability to penetrate the blood-brain barrier and could effectively kill brain metastatic cancer cells or malignant brain tumor cells.
ABM-168 has been granted its IND by the U.S. FDA in October 2022. A first in human Phase 1 clinical trial (NCT05831995) has been opened in several cancer centers in the United States.
ABM-168 is a highly potent allosteric MEK1/2 inhibitor, which can block the cancerous signaling pathway of cells caused by RAS and RAF mutation or signal amplification, thereby controlling the growth of cancer cells. The results of in vivo studies showed that when used alone, or in combination with other drugs in glioblastoma orthotopic models, human melanoma intracranial/intracardiac models, colon cancer subcutaneous transplantation models, colon cancer orthotopic tumors models and pancreatic cancer tumor models, ABM-168 shows great anti-tumor activity. It can effectively inhibit the proliferation of various RAS, RAF and NF1 mutated cancer cell lines. ABM-168 has an excellent ability to penetrate the blood-brain barrier and can effectively kill brain metastatic cancer cells or malignant brain tumor cells.
About ABM Therapeutics
A clinical-stage biopharmaceutical company with a mission to focus on small molecule research and development of novel drugs for the treatment of cancer, with an emphasis on blood–brain barrier (BBB) penetration and brain metastases. ABM’s pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet needs of treating cancers and metastases in the brain.